Sidney R. Baer, Jr. Foundation Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2017
NCT03781115
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Sidney R. Baer, Jr. Foundation

Active Ingredients

Drugs in Phase 1 Trials (2)

olanzapine (zyprexa) (1 trial)

ziprasidone (geodon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schizophrenia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2